Market Cap | 1.36B | P/E | - | EPS this Y | 20.60% | Ern Qtrly Grth | - |
Income | -217.44M | Forward P/E | -8.20 | EPS next Y | 17.30% | 50D Avg Chg | -5.00% |
Sales | 591k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -11.00% |
Dividend | N/A | Price/Book | 4.51 | EPS next 5Y | - | 52W High Chg | -35.00% |
Recommedations | 1.80 | Quick Ratio | 7.85 | Shares Outstanding | 120.03M | 52W Low Chg | 27.00% |
Insider Own | 26.12% | ROA | -48.56% | Shares Float | 54.18M | Beta | - |
Inst Own | 68.07% | ROE | -99.59% | Shares Shorted/Prior | 16.57M/15.89M | Price | 14.03 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 406,400 | Target Price | 13.40 |
Oper. Margin | -35,535.53% | Earnings Date | - | Volume | 317,036 | Change | -5.46% |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
HC Wainwright & Co. | Buy | Aug 9, 24 |
HC Wainwright & Co. | Buy | May 20, 24 |
Citigroup | Buy | May 16, 24 |
JP Morgan | Overweight | May 13, 24 |
Wedbush | Outperform | Apr 23, 24 |
Chardan Capital | Buy | Apr 22, 24 |
TD Cowen | Buy | Apr 8, 24 |
Wedbush | Outperform | Apr 3, 24 |
Wedbush | Outperform | Apr 2, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
GV 2019 GP, L.L.C. | 10% Owner 10% Owner | Jun 20 | Sell | 15.01 | 56,408 | 846,684 | 06/22/23 | |
GV 2019 GP, L.L.C. | 10% Owner 10% Owner | Jun 09 | Sell | 14.73 | 31,703 | 466,985 | 06/13/23 | |
GV 2019 GP, L.L.C. | 10% Owner 10% Owner | May 22 | Sell | 14.43 | 131,861 | 1,902,754 | 05/24/23 | |
GV 2019 GP, L.L.C. | 10% Owner 10% Owner | Oct 24 | Buy | 17 | 800,000 | 13,600,000 | 11,522,248 | 10/26/22 |